Genprex Inc (GNPX)

$0.19 -0.01 (-4.05%)
Market Cap 8.23M
Revenue (ttm) 0.00
Net Income (ttm) -21.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,076,800
Avg Vol 10,970,758
Day's Range N/A - N/A
Shares Out 42.91M
Stochastic %K 41%
Beta -0.71
Analysts Strong Buy
Price Target $7.50

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 774 4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
SM095
SM095 Oct. 4 at 10:36 PM
$INTS $TNMG $GNPX $SRXH $NVVE
0 · Reply
ProfessorDman1
ProfessorDman1 Oct. 4 at 3:08 PM
penny sub .50 cents on my WL: $INTS $TNMG $GNPX $SRXH $NVVE
3 · Reply
ninichou
ninichou Oct. 4 at 11:42 AM
$GNPX 🙂‍↔️🙂‍↔️😤
0 · Reply
AppleJuice14
AppleJuice14 Oct. 3 at 10:48 PM
$GNPX we’ll be at $0.25 be end of next week
0 · Reply
Caracasloco
Caracasloco Oct. 3 at 6:04 PM
$GNPX wtf i sell all my 75000 chicken nuggets
2 · Reply
Jpeel1972
Jpeel1972 Oct. 3 at 6:02 PM
$GNPX it’s not “If” the RS happens it is when. They have no choice. Be leery of any pumps less than a 50% run. The company is broke
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 6:01 PM
$GNPX LMFAOOOOOOOOO. Oh man who bought this piece of shit at .22 😂 you ain’t ever seeing that number again untill after the split and it drops from dollars back to cents lololololololololololol!!!!
0 · Reply
William_H_Bonney
William_H_Bonney Oct. 3 at 5:59 PM
$GNPX lol she wet the bed again. It could go two directions but of course old Gennie chose the south path.. if they conduct RS as the icing on the cake, the scam status is official..
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:59 PM
$GNPX SELLL SELLL SELLL! Don’t hold this garbage over the weekend you will wake up to it all being completely GONE!
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:58 PM
$GNPX lololololololololoillololololololololololololololo up 10% down 20% http://scam.com stay away from this stock.
0 · Reply
Latest News on GNPX
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 2, 2025, 8:30 AM EDT - 4 weeks ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 18, 2025, 9:29 AM EDT - 6 weeks ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 3 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 3 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 4 months ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 4 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 4 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 5 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 5 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 5 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 5 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 5 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 5 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 6 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 6 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 7 months ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 8 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 8 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 8 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 9 months ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 9 months ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 10 months ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 20, 2024, 9:29 AM EST - 11 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Nov 5, 2024, 9:29 AM EST - 11 months ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex to Participate in 2024 BIO Europe Conference

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Genprex to Present at the August Sidoti Microcap Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Genprex to Present at the 2024 BIO International Convention

May 30, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present at the 2024 BIO International Convention

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

May 14, 2024, 8:31 AM EDT - 1 year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

May 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

May 8, 2024, 6:08 PM EDT - 1 year ago

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

May 1, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Apr 9, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Apr 3, 2024, 8:31 AM EDT - 1 year ago

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Apr 2, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 22, 2024, 4:10 PM EDT - 1 year ago

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 1:24 PM EDT - 1 year ago

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SM095
SM095 Oct. 4 at 10:36 PM
$INTS $TNMG $GNPX $SRXH $NVVE
0 · Reply
ProfessorDman1
ProfessorDman1 Oct. 4 at 3:08 PM
penny sub .50 cents on my WL: $INTS $TNMG $GNPX $SRXH $NVVE
3 · Reply
ninichou
ninichou Oct. 4 at 11:42 AM
$GNPX 🙂‍↔️🙂‍↔️😤
0 · Reply
AppleJuice14
AppleJuice14 Oct. 3 at 10:48 PM
$GNPX we’ll be at $0.25 be end of next week
0 · Reply
Caracasloco
Caracasloco Oct. 3 at 6:04 PM
$GNPX wtf i sell all my 75000 chicken nuggets
2 · Reply
Jpeel1972
Jpeel1972 Oct. 3 at 6:02 PM
$GNPX it’s not “If” the RS happens it is when. They have no choice. Be leery of any pumps less than a 50% run. The company is broke
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 6:01 PM
$GNPX LMFAOOOOOOOOO. Oh man who bought this piece of shit at .22 😂 you ain’t ever seeing that number again untill after the split and it drops from dollars back to cents lololololololololololol!!!!
0 · Reply
William_H_Bonney
William_H_Bonney Oct. 3 at 5:59 PM
$GNPX lol she wet the bed again. It could go two directions but of course old Gennie chose the south path.. if they conduct RS as the icing on the cake, the scam status is official..
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:59 PM
$GNPX SELLL SELLL SELLL! Don’t hold this garbage over the weekend you will wake up to it all being completely GONE!
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:58 PM
$GNPX lololololololololoillololololololololololololololo up 10% down 20% http://scam.com stay away from this stock.
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:56 PM
$GNPX the play was +30 % from .16 it’s over lol.
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 5:51 PM
$GNPX WOOOOOOOOOOF give it all back day lol 😂 😂😂😂😂
0 · Reply
luckyCloud
luckyCloud Oct. 3 at 3:45 PM
$GNPX $PLUG open @ 2.93 right now near 4.0
1 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 2:45 PM
$GNPX to much selling pressure. Seeee yaaaa! Scam stay away from this stock http://scam.com
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 2:42 PM
$GNPX here it comes wait till all the guys that bought last week sell in a few min that fat red candle will finish off soon
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 2:39 PM
$GNPX hahahahahahaahaha! LIQUID!
0 · Reply
Howgdinguz
Howgdinguz Oct. 3 at 1:46 PM
$GNPX lol 😂, nope…. No one wants this garbage 😂 😂😂😂😂😂😂. Will sell off before 3pn today.
1 · Reply
position_trading
position_trading Oct. 3 at 1:28 PM
$GNPX they have a pending hearing regarding compliance. Hopefully they can make their case.
0 · Reply
luckyCloud
luckyCloud Oct. 3 at 1:16 PM
$GNPX AI Overview Genprex (GNPX) completed a 1-for-40 reverse stock split (RS) on February 2, 2024. And in 18th month next RS coming soon. $PLUG. Is the one, invest ur hard earn money in plug.
1 · Reply
ka1954
ka1954 Oct. 3 at 11:08 AM
$GNPX when is the RS annoucement ? been waiting long time for it to buy into this stock. LOL
3 · Reply
Caracasloco
Caracasloco Oct. 3 at 5:44 AM
$GNPX i have 75k pieces of chicken fries at 0.1485 go to 40 please
0 · Reply
Ebrice73
Ebrice73 Oct. 3 at 1:37 AM
$GNPX .48 tomorrow? Not yet… not yet 🫢
0 · Reply